Does Medicare cover Wegovy for heart disease?
Yes — but not the way most people think.
Medicare Part D doesn’t cover Wegovy for weight loss. It does cover Wegovy when it’s prescribed to lower the risk of heart attack, stroke, and cardiovascular death in adults who already have heart disease and are overweight or obese. The two situations look almost identical from the outside — same drug, same patient — but Medicare treats them very differently.
This guide explains the distinction, who qualifies under the cardiovascular indication, and what to expect from your Part D plan.
Since March 2024, Medicare Part D plans can cover Wegovy when it is prescribed to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and a BMI of 27 or higher. That is a separately approved FDA indication — not weight loss — and it is what makes Wegovy coverage legally possible under Part D.
Weight loss vs. heart-disease risk reduction.
Prescribed for weight loss alone
Federal law (the Medicare Modernization Act) bars Part D from covering drugs prescribed solely for chronic weight management. Without a separate qualifying diagnosis, Wegovy is out-of-pocket — typically $1,000–$1,400 per month.
The new GLP-1 Bridge Program (July 1, 2026) is the workaround for weight-loss-only patients.
Prescribed for cardiovascular risk reduction
In March 2024 the FDA approved Wegovy to reduce major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity or overweight. CMS quickly confirmed Part D plans can cover Wegovy under this cardioprotective indication.
Coverage here is treated as cardiac prevention — like a statin — not as weight management.
When Medicare covers Wegovy.
Wegovy for reducing risk of heart attack, stroke, or cardiovascular death in adults with established CVD + BMI ≥ 27
Covered by Medicare Part D since March 2024. Prior authorization with documentation of qualifying cardiovascular disease is typically required.
Wegovy for chronic weight management without a qualifying cardiac diagnosis.
Excluded by federal statute from Medicare Part D.
Wegovy for chronic weight management starting July 1, 2026
Covered by the new federal GLP-1 Bridge Program at $50/month for qualifying beneficiaries.
Coverage descriptions reflect federal Medicare guidance. Specific Part D plan rules, formulary tier, prior authorization, and step therapy may apply. Individual eligibility is determined clinically.
WHEN DOES MEDICARE COVER WEGOVY?
Medicare Part D may cover Wegovy for cardiovascular risk reduction when all four of the following requirements are met.
You have Medicare prescription coverage
Wegovy is covered through Medicare's prescription drug benefit. To qualify, you must have Medicare and prescription drug coverage through a Medicare Part D or Medicare Advantage plan.
You have established cardiovascular disease
Documented prior heart attack, prior stroke, or peripheral arterial disease. In addition to meeting BMI requirements, Medicare coverage under this indication requires a history of cardiovascular disease.
Your BMI is 27 or higher
The FDA cardiovascular indication applies to adults who are overweight (BMI ≥ 27) or obese (BMI ≥ 30) in addition to having established cardiovascular disease.
Wegovy is part of your cardiovascular care plan
Medicare coverage under this indication is based on Wegovy's ability to reduce cardiovascular risk in eligible patients with heart disease and overweight or obesity—not solely its effects on weight.
At Storm Wellness Northwest, we help patients with cardiovascular disease evaluate whether Wegovy is appropriate, coordinate prior authorization, and follow them through ongoing care.
Related guides.
Wegovy & Zepbound coverage in 2026
The full picture of Part D coverage today and the new Bridge Program launching July 1.
Wegovy vs Zepbound for Medicare
Why only Wegovy has the cardiovascular indication — and what that means for the choice between them.
GLP-1 side effects for seniors
What Medicare-age patients should watch for, and how to minimize the rough early weeks.
See whether the cardiovascular indication applies to you.
A consultation with Renee Storm, APRN reviews your cardiac history, current medications, and metabolic health — and clarifies whether Wegovy can be prescribed under the cardiovascular indication on your Part D plan.